SLC15A3 在调控巨噬细胞氧化应激中发挥关键作用,从而在肺纤维化中起作用。
SLC15A3 plays a crucial role in pulmonary fibrosis by regulating macrophage oxidative stress.
机构信息
Laboratory of Pharmaceutical Analysis and Drug Metabolism, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
Department of Clinical Pharmacy, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Hangzhou First People's Hospital, Hangzhou, China.
出版信息
Cell Death Differ. 2024 Apr;31(4):417-430. doi: 10.1038/s41418-024-01266-w. Epub 2024 Feb 19.
Idiopathic pulmonary fibrosis (IPF) is a fatal and irreversible disease with few effective treatments. Alveolar macrophages (AMs) are involved in the development of IPF from the initial stages due to direct exposure to air and respond to external oxidative damage (a major inducement of pulmonary fibrosis). Oxidative stress in AMs plays an indispensable role in promoting fibrosis development. The oligopeptide histidine transporter SLC15A3, mainly expressed on the lysosomal membrane of macrophages and highly expressed in the lung, has proved to be involved in innate immune and antiviral signaling pathways. In this study, we demonstrated that during bleomycin (BLM)- or radiation-induced pulmonary fibrosis, the recruitment of macrophages induced an increase of SLC15A3 in the lung, and the deficiency of SLC15A3 protected mice from pulmonary fibrosis and maintained the homeostasis of the pulmonary microenvironment. Mechanistically, deficiency of SLC15A3 resisted oxidative stress in macrophages, and SLC15A3 interacted with the scaffold protein p62 to regulate its expression and phosphorylation activation, thereby regulating p62-nuclear factor erythroid 2-related factor 2 (NRF2) antioxidant stress pathway protein, which is related to the production of reactive oxygen species (ROS). Overall, our data provided a novel mechanism for targeting SLC15A3 to regulate oxidative stress in macrophages, supporting the therapeutic potential of inhibiting or silencing SLC15A3 for the precautions and treatment of pulmonary fibrosis.
特发性肺纤维化(IPF)是一种致命且不可逆转的疾病,目前治疗方法有限。肺泡巨噬细胞(AMs)由于直接暴露于空气中,从疾病初始阶段就参与了 IPF 的发生,并对外部氧化损伤(肺纤维化的主要诱因)产生反应。AMs 中的氧化应激在促进纤维化发展中起着不可或缺的作用。寡肽组氨酸转运蛋白 SLC15A3 主要表达在巨噬细胞的溶酶体膜上,在肺部高度表达,已被证明参与先天免疫和抗病毒信号通路。在这项研究中,我们证明了在博来霉素(BLM)或辐射诱导的肺纤维化中,巨噬细胞的募集诱导 SLC15A3 在肺部的增加,而 SLC15A3 的缺乏则保护小鼠免受肺纤维化并维持肺微环境的平衡。从机制上讲,SLC15A3 的缺乏抵抗了巨噬细胞中的氧化应激,并且 SLC15A3 与支架蛋白 p62 相互作用以调节其表达和磷酸化激活,从而调节 p62-核因子红细胞 2 相关因子 2(NRF2)抗氧化应激途径蛋白,与活性氧(ROS)的产生有关。总的来说,我们的数据为靶向 SLC15A3 以调节巨噬细胞中的氧化应激提供了一种新的机制,支持了抑制或沉默 SLC15A3 预防和治疗肺纤维化的治疗潜力。